Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?

References

• Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood 2013;122(25):4021-34
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Linhares Y, Gore SD. Current therapy of myelodysplastic syndromes. Blood Rev 2013;27(5):243-59
   PubMed Web of Science ®Google Scholar
• Raza A, Galili N. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. Nat Rev Cancer 2012;12(12):849-59
   PubMed Web of Science ®Google Scholar
• Faltas B, Zeidan A, Gergis U. Myelodysplastic syndromes: toward a risk-adapted treatment approach. Expert Rev Hematol 2013;6(5):611-24
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Smith BD, Komrokji RS, Gore SD. Prognostication in myelodysplastic syndromes: beyond the International Prognostic Scoring System (IPSS). Am J Med 2013;126(4):e25
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Komrokji RS. There's risk, and then there's risk: the latest clinical prognostic risk stratification models in myelodysplastic syndromes. Curr Hematol Malig Rep 2013;8(4):351-60
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89(6):2079-88
   PubMed Web of Science ®Google Scholar
• Bejar R. Prognostic models in myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2013;2013:504-10
   PubMed Web of Science ®Google Scholar
• Naqvi K, Jabbour E, Bueso-Ramos C, et al. Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood 2011;118(17):4690-3
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Kharfan-Dabaja MA, Komrokji RS. Beyond hypomethylating agents failure in patients with myelodysplastic syndromes. Curr Opin Hematol 2013. [Epub ahead of print]
   Google Scholar
• Kittaneh M, Montero AJ, Gluck S. Molecular profiling for breast cancer: a comprehensive review. Biomark Cancer 2013;5:61-70
   PubMedGoogle Scholar
• Maak M, Simon I, Nitsche U, et al. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Ann Surg 2013;257(6):1053-8
   PubMed Web of Science ®Google Scholar
• Pellagatti A, Benner A, Mills KI, et al. Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes. J Clin Oncol 2013;31(28):3557-64
   PubMed Web of Science ®Google Scholar
• Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2013;28(2):241-7
   Google Scholar
• Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013;122(22):3616-27
   PubMed Web of Science ®Google Scholar
• Starczynowski DT, Vercauteren S, Telenius A, et al. High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood 2008;112(8):3412-24
   Google Scholar
• Tiu RV, Gondek LP, O'Keefe CL, et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood 2011;117(17):4552-60
   PubMed Web of Science ®Google Scholar
• Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364(26):2496-506
   PubMed Web of Science ®Google Scholar
• Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012;30(27):3376-82
   PubMed Web of Science ®Google Scholar
• Sridhar K, Ross DT, Tibshirani R, et al. Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression. Blood 2009;114(23):4847-58
   Google Scholar
• Ebert BL, Galili N, Tamayo P, et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 2008;5(2):e35
   PubMed Web of Science ®Google Scholar
• Cilloni D, Gottardi E, Messa F, et al. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol 2003;21(10):1988-95
   PubMed Web of Science ®Google Scholar
• Pellagatti A, Marafioti T, Paterson JC, et al. Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. Br J Haematol 2009;146(1):86-90
   Google Scholar
• Chavan SS, Bauer MA, Peterson EA, et al. Towards the integration, annotation and association of historical microarray experiments with RNA-seq. BMC Bioinformatics 2013;14(Suppl 14):S4
   Google Scholar
• Bejar R, Abdel-Wahab O. The importance of subclonal genetic events in MDS. Blood 2013;122(22):3550-1
   Google Scholar